Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Sell
18
IKNA Quote, Financials, Valuation and Earnings
Last price:
$1.22
Seasonality move
:
7.53%
Day range:
$1.27 - $1.32
52-week range:
$1.22 - $1.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
6.74x
P/B ratio:
0.49x
Volume:
75.1K
Avg. volume:
79.4K
1-year change:
-9.86%
Market cap:
$61.8M
Revenue:
$9.2M
EPS (TTM):
-$1.01
Analysts' Opinion
-
Consensus RatingIkena Oncology has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.00, Ikena Oncology has an estimated upside of 134.38% from its current price of $1.28.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.28.
Fair Value
-
According to the consensus of 2 analysts, Ikena Oncology has 134.38% upside to fair value with a price target of $3.00 per share.
IKNA vs. S&P 500
-
Over the past 5 trading days, Ikena Oncology has underperformed the S&P 500 by -6.27% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Ikena Oncology does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ikena Oncology revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Ikena Oncology reported revenues of --.
Earnings Growth
-
Ikena Oncology has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ikena Oncology reported earnings per share of -$0.19.
Enterprise value:
-62.6M
EV / Invested capital:
--
Price / LTM sales:
6.74x
EV / EBIT:
--
EV / Revenue:
-6.84x
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.36x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $15.6M | $9.2M | -- | $659K | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$70.9M | -$75.4M | -$54.6M | -$21.9M | -$12.2M | |
| EBITDA | -$70.2M | -$74.4M | -$54.1M | -$21.6M | -$12.1M | |
| Diluted EPS | -$1.91 | -$1.63 | -$1.01 | -$0.40 | -$0.19 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $166M | $236.5M | $160M | $178.7M | $127.2M | |
| Total Assets | $168.4M | $247.9M | $172.3M | $192.1M | $141.5M | |
| Current Liabilities | $28.3M | $27.2M | $21.5M | $14.2M | $10.8M | |
| Total Liabilities | $269.5M | $40M | $25.3M | $22.3M | $15.6M | |
| Total Equity | -$101M | $207.9M | $147M | $169.8M | $125.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$74.1M | -$79.7M | -$46M | -$21.8M | -$6.3M | |
| Cash From Investing | -$99.3M | $64.1M | -$34.9M | $20.4M | $463K | |
| Cash From Financing | $1.1M | -- | -- | $60K | -- | |
| Free Cash Flow | -$75.5M | -$80.2M | -$46M | -$22.1M | -$6.3M | |
IKNA
Sector
Market Cap
$61.8M
$37M
Price % of 52-Week High
65.98%
43.14%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.03%
1-Year Price Total Return
-9.86%
-43.58%
Beta (5-Year)
--
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.33
200-day SMA
Sell
Level
$1.62
Bollinger Bands (100)
Sell
Level
1.4 - 1.68
Chaikin Money Flow
Sell
Level
-10.6M
20-day SMA
Sell
Level
$1.34
Relative Strength Index (RSI14)
Sell
Level
39.30
ADX Line
Sell
Level
10.59
Williams %R
Buy
Level
-81.4126
50-day SMA
Sell
Level
$1.41
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-20
On Balance Volume
Neutral
Level
5.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.2753)
Sell
CA Score
(Annual)
Level (-0.6169)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (4.2186)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.
Stock Forecast FAQ
In the current month, IKNA has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The IKNA average analyst price target in the past 3 months is $3.00.
-
Where Will Ikena Oncology Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ikena Oncology share price will rise to $3.00 per share over the next 12 months.
-
What Do Analysts Say About Ikena Oncology?
Analysts are divided on their view about Ikena Oncology share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ikena Oncology is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Ikena Oncology's Price Target?
The price target for Ikena Oncology over the next 1-year time period is forecast to be $3.00 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is IKNA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ikena Oncology is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of IKNA?
You can purchase shares of Ikena Oncology via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ikena Oncology shares.
-
What Is The Ikena Oncology Share Price Today?
Ikena Oncology was last trading at $1.22 per share. This represents the most recent stock quote for Ikena Oncology. Yesterday, Ikena Oncology closed at $1.28 per share.
-
How To Buy Ikena Oncology Stock Online?
In order to purchase Ikena Oncology stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 Smartest Dividend Stocks to Buy Now
When the market entered a correction in February and March,…
How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.6T
P/E Ratio: 37x
Alerts
Buy
80
CORT alert for Apr 1
Corcept Therapeutics [CORT] is down 19.56% over the past day.
Sell
16
PCVX alert for Apr 1
Vaxcyte [PCVX] is down 14.62% over the past day.
Buy
74
COOP alert for Apr 1
Mr. Cooper Group [COOP] is up 4.63% over the past day.
